SRPT Earnings Prediction
The chart below shows how SRPT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SRPT sees a +3.45% change in stock price 10 days leading up to the earnings, and a +5.45% change 10 days following the report. On the earnings day itself, the stock moves by +1.36%. This data can give you a slight idea of what to expect for the next quarter's release.
SRPT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
467.17M
40.79%
28.72%
Gross Margin
80.24%
-9.55%
-8.36%
Operating Margin
4.75%
175.64%
-2600.00%
Net Margin
7.19%
158.27%
303.93%
EPS
0.34
173.91%
385.71%
No Data Available
SRPT Earnings Analysis
Sarepta Therapeutics,, Inc. Common Stock Corporation (SRPT.O) Earnings Conference Call
Positive
Q3 Revenue Surge: 1. Strong Revenue Growth: Sarepta reported total net product revenue of approximately $430 million for Q3 2024, reflecting a 39% increase compared to the same quarter last year.
ELEVIDYS Revenue Surge: 2. ELEVIDYS Performance: Net product revenue for ELEVIDYS reached $181 million in Q3 2024, growing nearly 50% from the previous quarter and significantly exceeding prior guidance.
PMO Sales Revenue Growth: 3. PMO Franchise Success: The PMO sales, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, generated approximately $249 million in revenue for Q3 2024, showing a healthy growth of nearly 15% year-over-year.
Profitability Improvement: 4. Profitability Achieved: Sarepta reported a GAAP net income of $33.6 million for Q3 2024, a significant improvement from a net loss of $40.9 million in the same quarter of 2023.
Cash Reserves for Growth: 5. Strong Cash Position: As of September 30, 2024, Sarepta had approximately $1.4 billion in cash, cash equivalents, and investments, positioning the company well for future growth and development.
Negative
PPMO Program Discontinuation: 1. Discontinuation of PPMO Program: Sarepta has decided to discontinue the SRP-5051 development program due to safety concerns, particularly persistent hypomagnesemia, which led to a risk-benefit analysis that deemed further development unviable.
R&D Expense Increase: 2. Increased R&D Expenses: R&D expenses rose to $224.5 million in Q3 2024, up from $194.3 million in Q3 2023, primarily due to a $55.4 million cost associated with the termination of a commercial manufacturing agreement.
Rising Cost of Sales: 3. Higher Cost of Sales: The cost of sales increased significantly to approximately $91.7 million in Q3 2024, compared to $37 million in the same period of 2023, reflecting the costs associated with the sales of ELEVIDYS.
PMO Growth Slowdown: 4. Decline in PMO Growth Rate: The PMO sales growth was only about 4% in Q3 2024 compared to the same quarter in 2023, indicating a slowdown in growth for this segment amid the launch of ELEVIDYS.
Strategic Investment Impairment: 5. Impairment of Strategic Investment: The company recorded a net loss of $40.9 million in Q3 2023, which included an impairment of a strategic investment, highlighting financial challenges faced in the previous year.
SRPT FAQs
How does SRPT typically perform around its earnings report dates?
Is Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SRPT Earning Call Sentiment
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SRPT.O
-2.71%Positive
The earnings call summary reflects strong financial performance with a 39% YoY revenue growth and significant demand for ELEVIDYS, despite increased R&D expenses. The company is cash flow positive, with a promising outlook for 2025 revenue. The Q&A highlighted management's confidence in guidance and productive payer interactions, although some responses lacked clarity. The absence of a share repurchase program is neutral. Overall, the positive financial metrics and optimistic guidance suggest a positive stock price reaction over the next two weeks.
